VALSARTAN LOSARTAN AND IRBESARTAN PRODUCTS LIABILITY LITIGATION
Case Number:
1:19-md-02875
Court:
Nature of Suit:
Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability
Multi Party Litigation:
Multi-district Litigation
Judge:
Firms
- Ahmuty Demers
- Archer & Greiner
- Baker Donelson
- Baker & Hostetler
- Barnes & Thornburg
- Beasley Allen
- Beasley Firm
- Benesch
- Buchanan Ingersoll
- Bursor & Fisher
- Chaffin Luhana LLP
- Cipriani & Werner
- Cohen Placitella
- Crowell & Moring
- Davis & Crump
- Donahey Law
- Douglas & London
- Duane Morris
- Eimer Stahl
- Eisenberg Rothweiler
- Erlanger Law Firm
- Fears Nachawati
- Gainey McKenna
- Golomb Spirt
- Grant & Eisenhofer
- Greenbaum Rowe
- Greenberg Traurig
- Guerra LLP
- Hardin Kundla
- Hill Wallack
- Hinshaw & Culbertson
- Hofeld & Schaffner
- Husch Blackwell
- Kanner & Whiteley
- Kirkland & Ellis
- Krivit Law
- Labaton Keller
- Law Office of Adam R. Gonnelli
- Law Office of Barry R. Glazer
- Lewis Brisbois
- Lowey Dannenberg
- Marshall Dennehey
- Mazie Slater
- Messa & Associates
- Miller Shah LLP
- Morgan Lewis
- Murphy & Dunn
- Nagel Rice
- Napoli Shkolnik
- ND Galli Law LLC
- Novitzke Gust
- Oliver Bell Group
- Parafinczuk Wolf
- Pietragallo Gordon
- Polsinelli PC
- Powell Kugelman
- Rawle & Henderson
- Rheingold Giuffra
- Rueb Stoller
- Saul Ewing
- Sills Cummis
- Skadden Arps
- Stark & Stark
- Sullivan Papain
- Troutman Pepper
- Walsh Pizzi
- Wheeler Trigg
- Wong Fleming
- Wood Smith
- Zareh & Associates
- Zoll & Kranz
Companies
- Albertsons Cos. Inc.
- Allergan PLC
- Amneal Pharmaceuticals Inc.
- A-S Medication Solutions LLC
- Aurobindo Pharma Ltd.
- Avkare Inc.
- Camber Pharmaceuticals Inc.
- Cardinal Health Inc.
- Cencora Inc.
- CVS Health Corp.
- Express Scripts Holding Co.
- GSMS Inc.
- Harris Teeter Supermarkets, Inc.
- Hetero Drugs Ltd.
- Hetero Labs Ltd.
- Humana Inc.
- Hy-Vee
- Jubilant Cadista
- LifeWallet
- McKesson Corp.
- NuCare Pharmaceuticals Inc.
- Optum Inc.
- OptumRx Inc.
- Prime Therapeutics LLC
- Prinston Pharmaceutical Inc.
- Red Oak Sourcing LLC
- Rite Aid Corp.
- ScieGen Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- The Cigna Group
- The Harvard Drug Group LLC
- The Kroger Co.
- The Linde Group
- Torrent Pharmaceuticals Ltd.
- Viatris Inc.
- Village Super Market Inc.
- Walgreens Boots Alliance Inc.
- Walmart Inc.
- Weis Markets Inc.
Sectors & Industries:
-
December 18, 2020
No Preemption In Blood Pressure Drug Contamination MDL
A New Jersey federal judge won't let manufacturers, wholesalers and pharmacies escape multidistrict litigation over their alleged failure to keep contamination out of the blood pressure drug Valsartan, saying federal law doesn't preempt claims by buyers and users of the drug.
-
September 21, 2020
Buyers Fight CVS, Walgreens' Bid To Exit Blood Pressure MDL
A class of consumers urged a New Jersey federal court to reject attempts by Walgreens, CVS and Rite Aid to escape multidistrict litigation alleging they misrepresented a generic high blood pressure drug, saying the pharmacies are shirking obligations by calling themselves drug testers instead of sellers.
-
July 20, 2020
CVS, Walgreens Want Out Of Blood Pressure Drug MDL
Pharmacies including CVS and Walgreens have urged a New Jersey federal judge to drop them from multidistrict litigation alleging they misrepresented a generic high blood pressure drug, arguing that the allegations are barred by federal law and that all liability lies with the manufacturers, not the pharmacies.
-
February 27, 2020
Judge Says Attys Didn't 'Get The Message,' Can't Drop Clients
A New Jersey federal magistrate judge Thursday rejected a second attempt by three attorneys to withdraw as counsel for two clients in multidistrict litigation over a contaminated blood pressure drug, saying they need to explain how they tried to get in contact with their unresponsive clients.
-
September 24, 2019
Want Your Rival's Funder Info? Be Specific, Or Don't Bother
A recent opinion by a New Jersey federal judge in multidistrict litigation over a contaminated blood pressure drug further undercuts the use of speculative arguments about the risks of third-party legal financing and requirements for blanket disclosures, experts said.
- ← Previous
- 1
- 2
- Next →